Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Summary

The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.

Timeline

Start

2017-07-24

Primary completion

2018-06-25

Completion

2018-06-25

Outcome

Missed primary endpoint

registry analysis (other test); LIK066 vs Placebo; p = 0.353; Ratio LIK066/Placebo 0.88 (90% CI 0.70 to 1.11); t-test, 2 sided NCT03152591 ↗

Drugs

Indications